Close
Patheon

News Releases

  • 11 Oct 2016

    Company Commences Search for a New CFO

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE:PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today announced that its executive vice president and chief financial officer, Stuart Grant, plans to retire in 2017. Grant will remain in his current role until a successor has been appointed and a transition has been completed. The company has initiated a search to identify amore...
  • 04 Aug 2016
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon (NYSE: PTHN) today announced the redemption of all outstanding 8.75%/9.50% Senior PIK Toggle Notes (“Notes”) due May 2020 issued by Patheon’s indirect subsidiary, JLL/Delta Dutch Pledgeco B.V. The Notes were issued in a May 2015 private placement. The redemption price includes $550 million in principal, 2.0 percent premium, and accrued and unpaid interest in the amount of $12.3 million. To redeem the outstanding debt Patheonmore...
  • 26 Jul 2016
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. ("Patheon" or the "company") (NYSE: “PTHN”) today announced the closing of its previously announced initial public offering of 34,226,191 of its ordinary shares at a public offering price of $21.00 per share, including 4,761,905 ordinary shares sold by the selling stockholder identified in the prospectus and 4,464,286 ordinary shares sold pursuant to the option granted to the underwriters to purchase additional ordinarymore...